Competition & Peer Data API & CSV Delivery

Valion Bio Inc's Competitiveness

Name: Valion Bio Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Valion Bio Inc (VBIO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

Competitors Tracked

Publicly traded peers

Peer Group Market Share

vs 0.00 % a year ago

Revenue Growth Y/Y

Peers: 13.23 %

Net Margin

Peers: 14.81 %

Key Findings: Valion Bio Inc vs Its Competitors

Scale: Valion Bio Inc ranks #215 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/VBIO/competitors                    

                        https://api.csimarket.com/api/v1/companies/VBIO/relationships                    

                        https://api.csimarket.com/api/v1/companies/VBIO/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Valion Bio Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Valion Bio Inc	-	-	-	No
Competitors combined (9)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

VBIO Stock Performance relative to its Competitors

VBIO Competitors (weighted) Percent change over the selected range

Valion Bio Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Competitors Combined
(3 of 9)

Similar-Size
(0 of 4)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Valion Bio Inc	0.20 %	Underperformed
Competitors combined (9)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (4)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Valion Bio Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

VBIO Stock Performance relative to Similar-Size Competitors

VBIO Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#	Competitor	TTM Share Price Return	vs U.S.A. 500
1	Avadel Pharmaceuticals Plc	282.9%	Outperformed
2	Electrocore Inc	282.9%	Outperformed
3	Brainsway Ltd	282.9%	Outperformed
4	Medtronic Plc	282.9%	Outperformed
5	Inspire Medical Systems inc	282.9%	Outperformed

Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Valion Bio Inc's best-performing tracked competitors requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API, trailing 12 months.

Valion Bio Inc's Comment on Competition and Industry Peers

The company operates in the competitive contract development and manufacturing organization (CDMO) services market, competing with established firms that have greater financial resources, technical capabilities, infrastructure, and industry relationships. It acquired assets from Scorpius, which were previously part of a company that encountered significant financial difficulties. The company faces risks associated with integrating these assets and retaining essential personnel. Additionally, limitations in pursuing the Section 505(b)(2) regulatory pathway may allow new competitive products to enter the market more rapidly, potentially affecting the company's competitive position. The company also faces risks related to protecting its intellectual property and trade secrets, which may be independently developed or disclosed by competitors. Competitors identified in filings include Scorpius and Velocity Bioworks.

Publicly Traded Peers of Valion Bio Inc

Revenue and income for trailing 12 months, in millions of $, except employees

Company	Market Cap	Revenues	Income	Employees
Valion Bio Inc	0.37	-	-18.79	-
Medtronic Plc	115,016.45	37,542.00	5,269.00	95,000
Avadel Pharmaceuticals Plc	2,189.59	248.76	-0.28	154
Inspire Medical Systems inc	2,025.86	899.23	135.04	1,333
Solana Company	217.93	9.59	-136.85	21
Electrocore Inc	103.73	36.53	-14.77	83
SUBTOTAL	119,570.74	38,905.82	5,158.97	97,089

4 more competitors available

Sources: Valion Bio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on: September 26, 2026
Focus of this report: publicly traded companies. Ten additional tables on Valion Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Valion Bio Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Rhinosystems Inc.	Named by the company	85%	2022 to 2026	3
ClearUP	Named by the company	85%	2022 to 2026	3
Vapore LLC	Named by the company	85%	2022 to 2026	3
NeilMed	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Valion Bio Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Valion Bio Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).

Company	Largest Segment	2nd Segment	3rd Segment
Medtronic Plc	CARDIOVASCULAR 38.34 %	Neuroscience Group 28.37 %	Medical Surgical 24.10 %
Avadel Pharmaceuticals Plc	Reportable 100.00 %	-	-

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Valion Bio Inc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $

Company	Market Cap	Revenue / Employee	Income / Employee
Valion Bio Inc	0	-	-
Medtronic Plc	115,016	395,179	55,463
Avadel Pharmaceuticals Plc	2,190	1,615,338	-1,805
Inspire Medical Systems inc	2,026	674,589	101,307
Solana Company	218	456,619	-6,516,714
Electrocore Inc	104	440,084	-177,952
PEERS TOTAL	119,570	400,723	53,330

4 more Peers available

Valion Bio Inc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.

Company	Largest Market	2nd Market	3rd Market
Medtronic Plc	United States 49.83 %	Total Other Countries, Excluding United States and Ireland 49.77 %	Ireland 0.40 %
Inspire Medical Systems inc	United States 95.93 %	Non-US 4.40 %	-

Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Valion Bio Inc's Position in Industry Market Structure

Market-capitalization share and concentration across all 222 companies in Valion Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.

Valion Bio Inc ranks #215 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 587, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).

Rank	Company	Market Cap	Industry Share
1	Intuitive Surgical Inc	145,832	13.38 %
2	Medtronic Plc	113,372	10.40 %
3	Stryker Corp	105,405	9.67 %
4	3m Company	88,542	8.12 %
5	Boston Scientific Corporation	1,234	5.2%
6	Becton Dickinson And Company	1,234	5.2%
7	Edwards Lifesciences Corporation	1,234	5.2%
8	Dexcom Inc	1,234	5.2%
9	Resmed Inc	1,234	5.2%
10	Alcon inc	1,234	5.2%
215	Valion Bio Inc	0	0.00 %

Full Industry Market Structure

Market cap and industry share for the rest of Valion Bio Inc's industry peers requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.

Valion Bio Inc's Same-Size Peers & Stock Performance

Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.

Rank	Company	Market Cap	TTM Return	3M Momentum	Beta	Sharpe (1Y)
210	Glucotrack Inc	1	-68.79 %	496.88 %	1.56	0.56
211	Encision Inc	1	-	-	-2.28	1.33
212	Therapeutic Solutions International Inc	0	-	-	0.06	-1,000,000.00
213	Vicarious Surgical Inc	0	-98.87 %	-66.49 %	1.89	-0.91
214	Catheter Precision Inc	1,234	12.3%	4.5%	1.10	0.80
215	Valion Bio Inc	0	0.18 %	500.30 %	1.32	-1.89
216	Ir med Inc	1,234	12.3%	4.5%	1.10	0.80
217	Nuwellis Inc	1,234	12.3%	4.5%	1.10	0.80
218	Omnia Wellness Inc	1,234	12.3%	4.5%	1.10	0.80
219	Strata Skin Sciences Inc	1,234	12.3%	4.5%	1.10	0.80
220	Better Therapeutics Inc	1,234	12.3%	4.5%	1.10	0.80

Full Same-Size Peer Performance

Market cap, return, momentum, beta and Sharpe ratio for the rest of Valion Bio Inc's same-size peers requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.

Valion Bio Inc's Valuation vs Competitive Position

Valuation multiples vs the Medical Equipment & Supplies industry average (288 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.

Metric	Company	Industry Average	Difference
P/E	-	34.6x	-
EV / EBITDA	-	19.7x	-
P/B	0.0x	4.7x	-4.7x
Return on Equity	-199.34 %	industry aggregate	-211.40 %
Return on Invested Capital	-55.68 %	-2.32 % (avg)	-53.36 %

Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.

Valion Bio Inc's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.

Metric	2019	2024	2025
Revenue Growth	-	-33.67 %	-38.21 %
Operating Margin	-	-725.77 %	-1,665.35 %
Return on Invested Capital	-191.87 %	-96.08 %	-48.36 %
P/E	-	-	-

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Valion Bio Inc's BCG Growth-Share Matrix

Relative market share (vs Valion Bio Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.

Valion Bio Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).

Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.

Valion Bio Inc's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.

Force	Assessment	Basis
Competitive Rivalry	High	Industry HHI of 587 (see Industry Market Structure & Concentration above)
Supplier Power	Not covered on this page	See Valion Bio Inc's dedicated suppliers page for concentration and dependency data
Buyer Power	Not covered on this page	See Valion Bio Inc's dedicated customers page for concentration and dependency data
Threat of Substitutes	-	No systematic data source for cross-product substitution exists in this system; not estimated

Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.

Valion Bio Inc's Industry Attractiveness & Competitive Strength

A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.

High Strength

Medium Strength

Low Strength

High Attractiveness

Invest / Grow

Selective

Medium Attractiveness

Invest / Grow

Selective

Harvest

Low Attractiveness

Selective

Harvest

Harvest / Divest Valion Bio Inc

Valion Bio Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.

Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.

Valion Bio Inc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

No rule matched.

Weaknesses

Return on equity 211.4 points below the industry aggregate.
Underperforming the U.S.A. 500 over the trailing 12 months.
Low relative market share vs the industry leader (0.00x).

Opportunities

No rule matched.

Threats

No rule matched.

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Valion Bio Inc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months

Company	Quick Ratio	Working Capital	Debt / Equity	Asset Turnover
Valion Bio Inc	3.66	4.14	0.58	-
Medtronic Plc	0.15	2.10	0.57	0.41
Avadel Pharmaceuticals Plc	1.14	2.76	-	1.38
Inspire Medical Systems inc	1.21	6.38	-	1.01
Solana Company	13.17	17.87	-	0.04
Electrocore Inc	0.63	1.26	-	2.01

4 more Peers available

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Valion Bio Inc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter

Company	Period	Revenue Y/Y	Revenue Q/Q	Income Y/Y	Income Q/Q
Valion Bio Inc	Q2 2026	-	-	-	-
Medtronic Plc	Q2 2026	+13.7 %	-0.5 %	+41.3 %	+17.5 %
Avadel Pharmaceuticals Plc	Q3 2025	+55.3 %	+14.3 %	-	-99.8 %
Inspire Medical Systems inc	Q2 2026	-7.3 %	-1.6 %	-	-
Solana Company	Q1 2026	+7,289.8 %	-30.7 %	-	-
Electrocore Inc	Q2 2026	+28.0 %	+0.9 %	-	-
PEERS TOTAL		+13.1 %	-0.5 %	+28.8 %	-14.2 %

4 more Peers available

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Valion Bio Inc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter

Company	Period	Costs Y/Y	Costs Q/Q	Capex Y/Y	Capex Q/Q
Valion Bio Inc	Q2 2026	-	-	-89.6 %	+714.3 %
Medtronic Plc	Q2 2026	+13.8 %	+0.5 %	-0.2 %	+1,017.8 %
Avadel Pharmaceuticals Plc	Q3 2025	-33.1 %	-35.3 %	-	-95.0 %
Inspire Medical Systems inc	Q2 2026	-14.3 %	+7.9 %	+1.8 %	-5.8 %
Solana Company	Q1 2026	+48.8 %	+0.0 %	-	-
Electrocore Inc	Q2 2026	+35.6 %	+27.3 %	-84.0 %	+100.0 %

4 more Peers available

Valion Bio Inc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover

Company	ROA	ROI	ROE	Receivables Turnover	Inventory Turnover
Valion Bio Inc	-	-	-	-	-
Medtronic Plc	5.71%	6.46%	10.64%	5.80	2.21
Avadel Pharmaceuticals Plc	-	-	-	6.27	1.78
Inspire Medical Systems inc	15.21%	16.34%	17.62%	8.25	0.80
Solana Company	-	-	-	3,196.33	0.51
Electrocore Inc	-	-	-	34.09	2.40

4 more Peers available

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Valion Bio Inc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book

Company	P/E	Price / Sales	PEG	P/CF	Price / Book
Valion Bio Inc	-	-	-	0.28	0.09
Medtronic Plc	263.24	3.06	-	275.16	2.26
Avadel Pharmaceuticals Plc	-	8.80	-	42.74	22.29
Inspire Medical Systems inc	15.45	2.25	0.13	97.24	2.45
Solana Company	-	22.73	-	66.32	1.10
Electrocore Inc	-	2.84	-	21.08	-
PEERS AVERAGE	23.18	3.07		219.00	2.30

4 more Peers available

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.